Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cadrenal TherapeuticsCVKD -1.97%30 FCF Yield % is -177.70 as of Aug. 05, 2026. GuruFocus rates CVKD with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Cadrenal Therapeutics ranks worse than 93.69% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cadrenal Therapeutics FCF Yield % Related Terms
Cadrenal Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Cadrenal Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cadrenal Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cadrenal Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Cadrenal Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cadrenal Therapeutics (CVKD) has a FCF Yield % of -177.70 as of Aug. 05, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cadrenal Therapeutics and its competitors. According to the industry distribution chart, Cadrenal Therapeutics ranks #1321 out of 1410 companies in the Biotechnology industry, placing it in the top 93.7%.
Is Cadrenal Therapeutics' FCF Yield % too high?
Cadrenal Therapeutics' current FCF Yield % is -177.70. Based on the distribution chart, Cadrenal Therapeutics ranks #1321 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cadrenal Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cadrenal Therapeutics' FCF Yield % compare to RVPH and IMNN?
According to the Biotechnology industry distribution chart, Cadrenal Therapeutics ranks #1321 out of 1410 companies for FCF Yield %. This places Cadrenal Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cadrenal Therapeutics and its competitors. Cadrenal Therapeutics's current FCF Yield % is -177.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cadrenal Therapeutics stock overvalued right now?
Cadrenal Therapeutics (CVKD) has a current FCF Yield % of -177.70. The current FCF Yield % is -177.70. Cadrenal Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Cadrenal Therapeutics (CVKD), the current FCF Yield % is -177.70 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
30GF Score
Get the complete analysis for CVKD
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVKD has been successfully added to your 
